Gilead Sciences Past Performance
Past criteria checks 4/6
Gilead Sciences has been growing earnings at an average annual rate of 6.7%, while the Biotechs industry saw earnings growing at 10.8% annually. Revenues have been growing at an average rate of 4.9% per year. Gilead Sciences's return on equity is 26.4%, and it has net margins of 20.6%.
Key information
6.7%
Earnings growth rate
7.6%
EPS growth rate
| Biotechs Industry Growth | 44.3% |
| Revenue growth rate | 4.9% |
| Return on equity | 26.4% |
| Net Margin | 20.6% |
| Last Earnings Update | 31 Mar 2023 |
Recent past performance updates
Recent updates
Earnings and Revenue History
Quality Earnings: GIS has a large one-off loss of $2.2B impacting its last 12 months of financial results to March 31 2023.
Growing Profit Margin: GIS's current net profit margins (20.6%) are higher than last year (16.4%).
Past Earnings Growth Analysis
Earnings Trend: GIS's earnings have grown by 6.7% per year over the past 5 years.
Accelerating Growth: GIS's earnings growth over the past year (23.7%) exceeds its 5-year average (6.7% per year).
Earnings vs Industry: GIS earnings growth over the past year (23.7%) exceeded the Biotechs industry -12%.
Return on Equity
High ROE: Whilst GIS's Return on Equity (26.45%) is high, this metric is skewed due to their high level of debt.